ArticleLipids in health and disease2025
Assessing the impact of aggressive versus intermediate LDL-C goal achievement in Asian adults: a retrospective cohort study using national health insurance service-senior cohort.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptimal low-density lipoprotein cholesterol (LDL-C) targets remain a subject of debate for Asian adults, whose cardiovascular risk profiles and treatment responses may differ physiologically from Western populations. Clarifying appropriate LDL-C management goals could enhance the clinical effectiveness of cardiovascular care, ultimately improving health outcomes in Asia. This study evaluated the impact of achieving intermediate versus aggressive LDL-C targets on the incidence of atherosclerotic cardiovascular disease (ASCVD) and all-cause death among Asian adults.
methodsThis retrospective cohort study used data from the senior cohort of the Korean National Health Insurance Service. Patients who had initiated statin therapy were included in the study. Patients were categorised into two groups based on the achieved LDL-C targets: intermediate and aggressive. The incidence rate ratios (IRRs) and hazard ratios (HRs) for ASCVD and all-cause death were calculated using multivariable time-dependent Cox regression and marginal structural models.
resultsA propensity score-matched retrospective cohort of 951 patients aged 52 years or older per group was identified. No significant differences were observed in the incidence of ASCVD events (IRR, 1.182; 95% confidence interval [CI], 0.926-1.507) or all-cause death (IRR, 1.223; 95% CI, 0.735-2.034) between individuals who achieved intermediate and aggressive LDL-C goals. Similarly, the HRs showed no significant differences in the risk of ASCVD events (HR, 0.943; 95% CI, 0.698-1.276) or all-cause death (HR, 1.082; 95% CI, 0.597-1.959) in the time-dependent Cox model or in the marginal structural model for ASCVD events (HR, 0.945; 95% CI, 0.699-1.279) and all-cause death (HR, 1.072; 95% CI, 0.592-1.941).
conclusionThese findings underscore the need for LDL-C management strategies tailored to the unique physiological and clinical characteristics of Asian populations. Such an individualized approach may facilitate more effective and patient-centered cardiovascular care, ultimately leading to improved health outcomes in Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.